Effect on the Atherogenic Marker Plasminogen Activator Inhibitor Type-1 of Addition of the ACE Inhibitor Imidapril to Angiotensin II Type 1 Receptor Antagonist Therapy in Hypertensive Patients with Abnormal Glucose Metabolism: A Prospective Cohort Study in Primary Care

By Yajima Ken   Shimada Akira  

Clinical Drug Investigation, Vol. 29, Iss. 12, 2009-12 ,pp. : 811-819

Adis International

Access to resources Recommend Favorite

Valsartan: a novel angiotensin Type 1 receptor antagonist

By Thürmann P.A.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 2, 2000-01 ,pp. : 337-350

Informa Healthcare

Access to resources Recommend Favorite

Pharmacological profile of ME3221, a novel angiotensin II receptor antagonist

By Nagura J.   Yasuda S.   Fujishima K.   Yamamoto M.   Hui C.   Kawano K.-i.   Katano K.   Ogino H.   Hachisu M.   Konno F.  

European Journal of Pharmacology, Vol. 274, Iss. 1, 1995-02 ,pp. : 201-211

Elsevier

Access to resources Recommend Favorite

The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials

By Mistry Nisha B   Westheim Arne S   Kjeldsen Sverre E  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 5, 2006-04 ,pp. : 575-581

Informa Healthcare

Access to resources Recommend Favorite

The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension

By Thomas G. Neil  

Drugs & Aging, Vol. 23, Iss. 2, 2006-01 ,pp. : 131-155

Adis International

Access to resources Recommend Favorite